Astrazeneca Ab

Igor Shamovsky

Stephen Connolly

Magnus Munck Af Rosenschöld

Martin Hemmerling

Nafizal Hossain

Grigorios Nikitidis

Lena Elisabeth Ripa

Anna Kristoffersson

Susanne Elisabeth Berglund

Johan Rune Michael Lundkvist

Michael Lundkvist

Balint Gabos

Pavol Zlatoidsky

Magnus Munck Af Rosenschold

Johan Rune Lundkvist

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).

Chemical compounds

The present invention provides a compound of a formula (I): 

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD). 

The invention provides compounds of formula (I): wherein R, R, A, Aand B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors. 

Hydantoin derivatives as metalloproteinase inhibitors

Growing community of inventors

Mölndal, Sweden

Igor Shamovsky